PipelineReview.com13h
Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
BAGSVAERD, Denmark I1, 2024 I Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, ...
PipelineReview.com13h
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
VANCOUVER, Canada I1, 2024 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...
PipelineReview.com13h
Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101
MONTREAL, Canada I1, 2024 I Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies ...
PipelineReview.com13h
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
ROCKVILLE, MD, USA I October 21, 2024 I REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the ...